Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Gordana Jovic et al.|Journal of Clinical Oncology|2015Cited by 419
Monogenic and polygenic determinants of sarcoma risk: an international genetic studyMandy L. Ballinger, David M. Thomas, David L. Goode et al.|The Lancet Oncology|2016Cited by 213